Sanofi ($SNYNF) announced an update on their ongoing clinical study. Sanofi’s recent clinical study, officially titled ‘A Phase 3, Randomized, ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has recommended granting ...

SAN ANTONIO -- Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab and pertuzumab (Perjeta) ...

Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

HHUKWINI - Prime Minister (PM) Mmiso Russell Dlamini receives the box of injectable Lenacapavir for PrEP, a new ...

Celltrion, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable ...

Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseasesQfitlia, the first antithrombin-lowering therapy for hemophilia, ...

Ouro Medicines’ BCMAxCD3 T cell engager antibody candidate, gamgertamig gets US FDA orphan drug designation to treat immune thrombocytopenia: South San Francisco Tuesday, Decemb ...

China NMPA approves Sanofi’s Qfitlia for haemophilia and Cablivi for acquired thrombotic thrombocytopenic purpura: Paris Friday, December 12, 2025, 09:00 Hrs [IST] The National ...

Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors.

SK Hynix leads Macquarie’s rankings as the top South Korean stock. The semiconductor manufacturer has strengthened its position in the memory chip market, particularly in DRAM and NAND flash memory ...

Microsoft and Qualcomm have made important improvements to compatibility and performance for games on Snapdragon CPUs. Microsoft and Qualcomm have made important improvements to compatibility and ...